eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 11/09/2007
SPC Brolene Eye Ointment


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Brolene Eye Ointment.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Dibrompropamidine isetionate 0.15% w/w.


Go to top of the page
3. PHARMACEUTICAL FORM

Ointment.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Dibrompropamidine isetionate is an aromatic diamidine which is active against Gram-positive non-spore forming organisms, but less active against Gram-negative bacteria and spore forming organisms. It also has antifungal properties. It may be used topically for the treatment of minor eye infections such as conjunctivitis and blepharitis.


Go to top of the page
4.2 Posology and method of administration

Adults, elderly persons and children: for the treatment of minor eye infections.

Apply topically once or twice daily. Medical advice should be obtained if there has been no significant improvement after two days.


Go to top of the page
4.3 Contraindications

Hypersensitivity to dibrompropamidine or any component of the preparation.


Go to top of the page
4.4 Special warnings and precautions for use

If vision is disturbed or symptoms become worse during therapy, discontinue use and consult a physician.

If there is no significant improvement after two days' therapy, discontinue use and consult a physician.

The eye ointment is unsuitable for use with hard or soft contact lenses.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Safety of use in pregnancy and lactation has not been established. Use during pregnancy and lactation only if considered essential by a physician.


Go to top of the page
4.7 Effects on ability to drive and use machines

Eye ointment will cause blurring of vision on instillation. Warn patients not to drive or operate hazardous machinery unless vision is clear.


Go to top of the page
4.8 Undesirable effects

Hypersensitivity may occur, in which case treatment should be discontinued immediately.


Go to top of the page
4.9 Overdose

Topical overdose not applicable. Oral ingestion of a full 5g tube is unlikely to cause any toxic effects.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Dibrompropamidine is a member of the aromatic diamidine group of compounds which possess bacteriostatic properties against a wide range of fungi and bacteria. These diamidines exert antibacterial action against pyrogenic cocci, antibiotic resistant staphylococci and some Gram-negative bacilli. The activity of the diamidines is retained in the presence of organic matter such as pus and blood.


Go to top of the page
5.2 Pharmacokinetic properties

No data available.


Go to top of the page
5.3 Preclinical safety data

No relevant data.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Paraffin soft yellow, Paraffin liquid, Lanolin anhydrous, Phenylethanol,Water for injections.


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

36 months. Use within 4 weeks of first opening


Go to top of the page
6.4 Special precautions for storage

Store below 25oC.


Go to top of the page
6.5 Nature and contents of container

Printed, internally lacquered aluminium collapsible tubes with screw capped nozzle fitted with a polythene cap containing 5g ointment.


Go to top of the page
6.6 Special precautions for disposal and other handling

No relevant instructions.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

sanofi-aventis

One Onslow Street

Guildford

Surrey

GU1 4YS


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 04425/0198


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

22 July 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

November 2006


Go to top of the page
11 LEGAL CLASSIFICATION

P



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/9938/SPC/


Active Ingredients/Generics

 
   dibrompropamidine isetionate